News

Press Releases

AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

03/12/2024

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Highly encouraging preclinical data highlight the

AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

15/11/2024

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants Clinical estimates for SP-B deficiency have an incidence of 1 in 1 million live

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

14/09/2023

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene

Events

AlveoGene Presents as Finalist in Innovator Pitch Challenge at RESO SFO 2025

AlveoGene’s Executive Chair David Hipkiss presented at 9.00 hrs PST (17.00 hrs GMT) on Tuesday 14th January at the RESI SFO 2025 Innovator Pitch Challenge.

A copy of the presentation is available for download here.

JPM Week 2025 and RESI San Francisco

Executive Chair, David Hipkiss, will be attending JPM 2025 week in San Francisco week beginning 13th January 2025.

He will be meeting with investors and partners and also presenting an overview of AlveoGene and its innovative technology and pipeline at RESI JPM 2025 which takes place in person on January 14 at the Marriott Marquis San Francisco (780 Mission St, San Francisco, CA 94103).

Please reach out to request a meeting at [email protected]

RESI London

Executive Chair, David Hipkiss, will be presenting as a Finalist in the Innovators Pitch Challenge at the RESI London Conference on 4th December 2024 at 11 Cavendish Square, London, UK. He will be meeting with a range of investors and potential partners. Please reach out to schedule a meeting and discuss AlveoGene’s innovative technology and pipeline at [email protected]

Jefferies London

Executive Chair, David Hipkiss, will be attending Jefferies Conference at The Waldorf Hotel, London, UK from 19-21st November. He will be meeting with a range of investors and partners. Please reach out to schedule a meeting and discuss AlveoGene’s innovative technology and pipeline at [email protected]

Inv€$tival London 2024

Executive Chair, David Hipkiss, will present an overview of AlveoGene and its innovative technology and pipeline at the Inv€$tival Showcase on Monday 19 November at 15.00 hrs GMT at the Tobacco Dock in London, UK.

2024 Oxford Harrington Rare Disease Symposium

AlveoGene is working in partnership with the Oxford-Harrington Rare Disease Centre this week at the 2024 Oxford Harrington Rare Disease Symposium, which is taking place at Trinity College Oxford from 24-26 September.

David Hipkiss, Executive Chair be presenting AlveoGene‘s outstanding year of progress as we continue on our mission to transform rare respiratory disease outcomes using inhaled gene therapy.

AlveoGene’s InGenuiTy® platform uniquely combines efficacy, durability and convenience with potential lifelong protection from a single dose.

The Company will provide updates on our pipeline progress and latest developments in neonatal surfactant protein deficiencies (Lethal SP-B and ABCA3), Alpha-1 anti-trypsin deficency (AATD), and IPF.